Genes of detoxification are important modulators of hereditary medullary thyroid carcinoma risk

Clinical Endocrinology

Volumn 79, Issue 2, 2013, Pages 288-293

  Barbieri, R B ^a   Bufalo, N E ^a   Cunha, L L ^a   Assumpcao L V M ^b   Maciel, R M B ^b   Cerutti, J M ^a   Ward, L S ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; GLUTATHIONE TRANSFERASE P1; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; DETOXIFICATION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INHERITANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA;

ADOLESCENT; ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; LOGISTIC MODELS; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880073299     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12136     Document Type: Article

References (24)

1. Ball, D.W., (2007) Medullary thyroid cancer: monitoring and therapy. Endocrinology and Metabolism Clinics of North America, 36, 823-837.
2. Hundahl, S.A., Fleming, I.D., Fremgen, A.M., et al,. (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer, 83, 2638-2648.
3. Roman, S., Lin, R., &, Sosa, J.A., (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer, 107, 2134-2142.
4. Romei, C., Cosci, B., Renzini, G., et al,. (2011) RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clinical Endocrinology(Oxford), 74, 241-247.
5. Elisei, R., Romei, C., Cosci, B., et al,. (2007) RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. The Journal of Clinical Endocrinology and Metabolism, 92, 4725-4729.
6. Frank-Raue, K., Buhr, H., Dralle, H., et al,. (2006) Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. European Journal of Endocrinology, 155, 229-236.
7. Brandi, M.L., Gagel, R.F., Angeli, A., et al,. (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. The Journal of Clinical Endocrinology and Metabolism, 86, 5658-5671.
8. Tuttle, R.M., Ball, D.W., Byrd, D., et al,. (2010) Medullary carcinoma. Journal of the National Comprehensive Cancer Network, 8, 512-530.
9. Zhou, P., Liu, J., Cheng, S.W., et al,. (2012) Hereditary medullary thyroid carcinoma: the management dilemma. Familial Cancer, 11, 157-165.
10. Ceolin, L., Siqueira, D.R., Ferreira, C.V., et al,. (2012) Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness. European Journal of Endocrinology, 166, 847-854.
11. Pasquali, D., Circelli, L., Faggiano, A., et al,. (2011) CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma. European Journal of Endocrinology, 164, 397-404.
12. Bufalo, N.E., Leite, J.L., Guilhen, A.C., et al,. (2006) Smoking and susceptibility to thyroid cancer: an inverse association with CYP1A1 allelic variants. Endocrine-Related Cancer, 13, 1185-1193.
13. Granja, F., Morari, J., Morari, E.C., et al,. (2004) Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Letters, 210, 151-157.
14. Granja, F., Morari, J., Morari, E.C., et al,. (2004) GST profiling may be useful in the screening for thyroid nodule malignancy. Cancer Letters, 209, 129-137.
15. Guilhen, A.C., Bufalo, N.E., Morari, E.C., et al,. (2009) Role of the N-acetyltransferase 2 detoxification system in thyroid cancer susceptibility. Clinical Cancer Research, 15, 406-412.
16. Barbieri, R.B., Bufalo, N.E., Secolin, R., et al,. (2012) Evidence that polymorphisms in detoxification genes modulate the susceptibility for sporadic medullary thyroid carcinoma. European Journal of Endocrinology, 166, 241-245.
17. de Lima Junior, M.M., Reis, L.O., Guilhen, A.C., et al,. (2012) N-acetyltransferase-2 gene polymorphisms and prostate cancer susceptibility in Latin American patients. Medical Oncology l, 29, 2889-2894.
18. Tamanaha, R., Camacho, C.P., Pereira, A.C., et al,. (2009) Evaluation of RET polymorphisms in a six-generation family with G533C RET mutation: specific RET variants may modulate age at onset and clinical presentation. Clinical Endocrinology (Oxford), 71, 56-64.
19. Hothorn, T., &, Leisch, F., (2011) Case studies in reproducibility. Brief Bioinformatics, 12, 288-300.
20. Excoffier, L., &, Lischer, H.E., (2010) Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Molecular Ecology Resources, 10, 564-567.
21. Faul, F., Erdfelder, E., Buchner, A., et al,. (2009) Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behavior Research Methods, 41, 1149-1160.
22. Kebebew, E., Ituarte, P.H., Siperstein, A.E., et al,. (2000) Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer, 88, 1139-1148.
23. Ward, L.S., Morari, E.C., Leite, J.L., et al,. (2007) Identifying a risk profile for thyroid cancer. Arquivos Brasileiros de Endocrinologia e Metabologia, 51, 713-722.
24. Machens, A., &, Dralle, H., (2008) Familial prevalence and age of RET germline mutations: implications for screening. Clinical Endocrinology (Oxford), 69, 81-87.